COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,627 Articles (22,913 medRxiv, 8,714 bioRxiv)

Most recent first Previous |  Page 950: Articles 9491-9500  | Next

An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant
Shishir, T. A., Jannat, T., Naser, I. B.
10.1101/2022.02.21.481269 — Posted: 2022-02-23
Cell-Mediated Immune Response after COVID 19 Vaccination in Patients with Inflammatory Bowel Disease
Caldera, F., Farraye, F., Necela, B., Cogen, D., Saha, S., Wald, A., Daoud, N., Chun, K., Grimes, I., Lutz, M., Swift, M. D., Virk, A., Bharucha, A. E., Patel, T., Gores, G. J., Chumsri, S., Hayney, M. S., Knuttson, K. L.
10.1101/2022.02.21.22271234 — Posted: 2022-02-23
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies
QI, M., Le Bert, N., Chan, W., Tan, M., Hang, S. K., Hariharaputran, S., Sim, J. X. Y., Low, J., Ng, W. L., Wan, W. Y., Ang, T. L., Bertoletti, A., Salazar, E.
10.1101/2022.02.21.22271127 — Posted: 2022-02-23
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
Shehab, M., Alrashed, F., Abdullah, I., Alfadhli, A., Ali, H., Abu-farha, M., Channanath, A., Abubaker, J., Al-Mulla, F.
10.1101/2022.02.22.22271342 — Posted: 2022-02-23
Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemic
Purshouse, K., Thomson, J. P., Vallet, M., Alexander, L., Bonisteel, I., Brennan, M., Cameron, D., Figueroa, J., Furrie, E., Haig, P., Heck, M., McCaughan, H., Mitchell, P. D., McVicars, H., Primrose, L., Templeton, K., Wilson, N., Hall, P. S.
10.1101/2022.02.22.22271041 — Posted: 2022-02-23
Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa
JASSAT, W., Abdool Karim, S., Mudara, C., Welch, R., Ozougwu, L., Groome, M., Govender, N., von Gottberg, A., Wolter, N., Wolmarans, M., Rousseau, P., Blumberg, L., Cohen, C.
10.1101/2022.02.22.21268475 — Posted: 2022-02-23
Early emergence phase of SARS-CoV-2 Delta variant in Florida
Cella, E., Ali, S., Schmedes, S. E., Rife, B., Marini, S., Salemi, M., Blanton, J., Azarian, T.
10.1101/2022.02.18.22271195 — Posted: 2022-02-22
Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell depleting therapy
Calabrese, C. M., Husni, E. M., Moss, B. M., Fernandez, A. J., Jin, Y., Kirchner, E., Calabrese, L. H.
10.1101/2022.02.21.22271289 — Posted: 2022-02-22
Psychological and financial impacts of COVID-19-related travel measures: An international cross-sectional study
McDermid, P., Sooppiyaragath, S., Craig, A., Sheel, M., Blazek, K., Talty, S., Seale, H.
10.1101/2022.02.21.22271299 — Posted: 2022-02-22
The efficacy, effectiveness and safety of SARS-CoV-2 disinfection methods (including ozone machines) in educational settings for children and young people
Edwards, D., Csontos, J. K., Gillen, E., Lewis, R., Cooper, A., Gal, M., Law, R.-J., Edwards, A.
10.1101/2022.02.21.22271281 — Posted: 2022-02-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).